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Background Pediatric drug development is hampered by practical, ethical, and scientific challenges. Microdosing is a promising new method to obtain pharmacokinetic data in children with minimal burden and minimal risk. The use of a labeled oral microdose offers the added benefit to study intestinal and hepatic drug disposition in children already receiving an intravenous therapeutic drug dose for clinical reasons.
Objective The objective of this study was to present pilot data of an oral [ 14 C]paracetamol [acetaminophen (AAP)] microdosing study as proof of concept to study developmental pharmacokinetics in children.
Methods In an open-label microdose pharmacokinetic pilot study, infants (0-6 years of age) received a single oral Conclusions We demonstrate the feasibility of using a [ 14 C]labeled microdose to study AAP pharmacokinetics, including metabolite disposition, in young children.
Introduction
Up to 70 % of drugs prescribed to children are unlicensed or off-label, which brings risk of drug toxicity or therapeutic failure [1, 2] . However, pediatric drug studies face important ethical, practical, and scientific challenges [3] . A major challenge-against the background of developmental changes in drug absorption, distribution, metabolism, and excretion-is appropriate dose selection [4] . Simple size-or weight-based extrapolations from adult to pediatric doses do not suffice, particularly in neonates and infants. Current strategies include simulations using population pharmacokinetic (popPK) and physiologically based pharmacokinetic (PBPK) models [5] [6] [7] [8] [9] . The usefulness of these models may be limited, as relatively little pediatric pharmacokinetic and physiological data are available to validate them. Hence, new data are needed to support these models, as well as alternative methods to collect pharmacokinetic data without the inherent risks of toxicity when a therapeutic dose is given for the first time in a specific age group.
Microdosing is an interesting alternative. The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) define a microdose as one-hundredth of the No Observed Adverse Effect Level (NOAEL) or predicted pharmacologic dose based on animal data or as 100 lg of the new drug, whichever dose is lower [10, 11] . Dose linearity between the microdose and therapeutic dose is a prerequisite to extrapolate pharmacokinetic data to dosing guidelines [12] . The extremely low dose concentrations call for highly sensitive measurements. Accelerator mass spectrometry (AMS) can measure low attomolar to zeptomolar isotope ratio ranges, to quantify [ 14 C]labeled drug or metabolite concentrations in urine or plasma samples, even after at least five half-lives following a microdose [13] . [ 14 C] Labeling of a microdose is associated with very low radiation exposure, i.e., less than 10 lSv in adults, when compared with the yearly background exposure of 2.5 mSv/year in The Netherlands [14] .
Hence, microdosing is safe to use to study pharmacokinetics in children. In clinical care, [ 14 C]urea has been safely used to test for Helicobacter pylori infection [15] . A [ 14 C]ursodiol microdose study in preterm infants was briefly described in an excellent review on the potential for use of AMS in children [16] . Administering a labeled oral microdose to children already receiving a therapeutic drug dose for clinical reasons intravenously offers the added possibility to study oral bioavailability [12, 17] . This approach may also serve to delineate developmental changes in the drug-metabolizing enzymes involved in intestinal and hepatic drug metabolism [17, 18] .
Paracetamol (acetaminophen; AAP), is much used in children and is an interesting study drug for several reasons. First, its metabolism shifts from primarily sulphation (AAP-sulphate [AAP-Sul]) to glucuronidation (AAP-glucuronide [AAP-Glu]) in the first year of life, as reflected by urinary metabolite kinetics [19, 20] . The relative contribution of intestinal and hepatic drug metabolism has not been studied to date. Second, dose linearity under normal conditions and after probenecid glucuronidation inhibition was shown in adults [18] . We therefore selected oral [ 14 C]AAP to study the developmental changes in AAP glucuronidation and sulphation in children already receiving the non-labeled or 'cold' drug intravenously for analgesia [14] . This paper presents our first pilot data as proof of concept of this promising, safe method to study developmental pharmacokinetics in children.
Methods

Study Design
This proof-of-concept study is part of a larger phenotyping study in 60 children delineating developmental changes in AAP to metabolite clearance (EudraCT 2011-005497-28). The Dutch Central Committee on Research Involving Human Subjects (The Hague, The Netherlands) approved the larger study. Parents or legal guardians gave informed consent. Radiation exposure was explained during the informed consent procedure in relation to background exposure and exposure from medical imaging. The Dutch Nuclear Research and Service Group estimated individual exposures at approximately 1 lSv for a 0-to 2-year-old child, well below the minimal risk category 1 (100 lSv) of the International Commission of Radiological Protection and the yearly background exposure (2.5 mSv). Category 1 risk studies are considered minimal risk and are allowed when they provide new scientific knowledge [11] .
Subjects
Patients admitted to the Intensive Care department of the Erasmus MC-Sophia Children's Hospital (Rotterdam, The Netherlands) were considered for inclusion. Inclusion criteria were age between 0 and 6 years, gestational age [36 weeks, medical need for intravenous AAP, and an indwelling central venous or arterial line in place. To reduce pharmacokinetic variability due to underlying disease, patients with kidney and liver injury or the use of more than one vasopressor drug were excluded, as well as children intolerant to enteral nutrition.
Study Procedures
A single oral [
14 C]AAP microdose (3.3 ng/kg, 60 Bq/kg, 0.25 mL/kg) followed by 1 mL of saline (to ensure rinsing of the enteral feeding tube) was administered in addition to the intravenous therapeutic dose of AAP (15 mg/kg intravenously every 6 h) prescribed by the treating physician to provide analgesia. The [
14 C]AAP oral dose also contained 1.7 lg/kg non-labeled AAP, but this amount was negligible in relation to the therapeutic intravenous dose and thus considered irrelevant for the pharmacokinetic estimations. The microdose was based on a previous adult [
14 C]AAP microdose study using 100 lg/7.1 kBq/individual and was normalized for weight [21] . Blood samples (0.5 mL) were taken from the indwelling catheter before and at 10-30 min, 1, 2, 4, 6, 12, and 24 h after dosing. Blood samples were centrifuged and plasma was stored at -80°C until analysis.
Medicinal Products
The AAP formulation (10 mg/mL) was purchased from Fresenius Kabi, Schelle, Belgium. [ 14 C]AAP was purchased from Moravek Biochemicals (Brea, CA, USA).
Radiopharmaceutical Preparation
The formulation for oral administration [ 14 Using 175 lL 100 % v/v methanol containing 6.6 lg/mL of AAP in 96-well protein precipitation plates, 45 lL of plasma was extracted. The pellet was washed with 100 lL 0.9 % NaCl :100 % methanol (1:4 v/v). Resulting filtrates were evaporated to dryness, and re-dissolved in 30 lL 10 mM ammonium phosphate pH3.4 (Eluent A) of which 25 lL was used for ultra performance liquid chromatography (UPLC) analysis. An AAP solution with a specific radioactivity of 4,100 Bq [ 14 C]AAP/100 lg AAP in blank pooled plasma was used to prepare eight calibrators levels and three quality control (QC) sample levels from 0.4 to 180 mBq/mL, and from 1.7 to 131 mBq/mL, respectively. Calibrators (duplicate), QCs (triplicate), and sample extracts were injected onto a UPLC coupled to a photodiode array (PDA). Chromatographic conditions can be found in Table 1 . AAP in 100 % methanol was added to each collected fraction to increase the carbon-12 content to 25 lg.
Accelerator Mass Spectrometry Analysis
[ 14 C]AAP and metabolites were determined as described recently [22] . A novel AMS sample introduction method was used in this study to allow the routine analysis of biomedical samples. The method consists of an automated carbon dioxide (CO 2 ) combustion device online coupled to an AMS. Briefly, dried fractionated samples are placed in a tin-foil cup and subsequently combusted using an elemental analyzer (EA) (Vario Micro, Elementar, Germany). The resulting CO 2 was captured on a zeolyte trap at the interface, connecting the EA to the AMS. CO 2 was released by heating of the trap and transferred to a vacuum syringe using helium. The resulting 6 % v/v gas mixture of CO 2 with helium was infused at a pressure of 1 bar at 60 lL/min into the titanium target in the SO110 ion source of a 1 MV Tandetron AMS (High Voltage Engineering Europe B.V., Amersfoort, The Netherlands) [23] . Within the source, CO 2 is converted into negative carbon ions. The validation for the liquid chromatography (LC) ? AMS analysis was based on the recommendation of the European Bioanalytical Forum. Three QC concentration levels were included: QC High 145 mBq/mL, QC Medium 14.5 mBq/ mL, and QC Low 2.4 mBq/mL. The accuracy of QC High, Medium, and Low analysis corresponded to 104, 103, and 90 %, respectively. The precisions, defined by a coefficient of variation, were 9.1, 6.7, and 6.9 %, respectively. All values are well within the requirements for LC ? AMS analysis [24] . The LLOQ of the method was 0.58 mBq/mL.
Data Analysis
Data were summarized as median (range), unless noted otherwise. The plasma [
14 C]AAP and metabolite concentrations were calculated by converting measured Bq/L to ng/L based on the dose given (3.3 ng/kg contained 60 Bq/ kg) and for the metabolites corrected for molecular weight ( 
Results
Patients
Between 13 January and 31 May 2014, 32 patients were eligible. Nine patients were excluded for logistical reasons and 13 for refusal of informed consent. Parents' informed consent was received for ten patients who were subsequently dosed according to the protocol. One patient vomited within 15 min post-dose and was excluded from pharmacokinetic analysis. Table 2 provides a summary of patient characteristics.
Detection of [ 14 C]AAP and Metabolites in Plasma
Time profiles of [ 
Discussion
This proof-of-concept study shows the practical and ethical feasibility of a [
14 C]microdose study in children to study developmental pharmacokinetics. The concentrations of [
14 C]AAP are in the expected range, when compared with dose-normalized concentrations previously reported in neonates and children [25] [26] [27] [18] . The apparent lack of an age-related difference in metabolite disposition is easily explained by our small sample size and the even smaller number of neonates in our cohort. This is supported by our observation that in the 4-day-old neonate [
14 C]AAP-4Sul concentrations are much higher than the [ 14 C]AAP-Glu concentrations, while the opposite is observed in the 2.4-year-old, in line with developmental changes in AAP metabolism. In the follow-up study up to 50 additional patients will be included to study developmental changes in AAP disposition with enough statistical power. Interestingly, the average t max values in our patients are much later than in the adult study: 0.25 versus 2.6 h for [26, 28] .
The major barrier to a [ 14 C]microdosing study in children has been the perceived risk of radiation in the context of a non-therapeutic trial [29, 30] . Still, radiation exposure in this study was extremely low (\1 lSv), much lower than yearly background exposure (2.5 mSv/year in The Netherlands), a continental flight ([4 lSv), exposure from chest X-ray (10 lSv), or computed tomography scans (100 lSv) [7, 14] . To overcome parental ethical barriers to the study, we added a letter from the Dutch collaborative patients' organization for rare and genetic diseases (VSOP) to the patient information leaflet, explaining the need for pediatric drug research and the minimal risk involved in this study. Surprisingly, from the informed consent conversations it appeared that most parents perceived there was minimal risk involved. Fear for harmful radiation exposure was not the main reason to deny informed consent. Parents of the other children refused informed consent for reasons relating to the burden of additional procedures and/or blood sampling. Very sensitive LC-tandem mass spectrometry (LC-MS/ MS) techniques to measure the pharmacokinetics of an unlabeled microdose may be an alternative to using a radiolabeled microdose in general [31] . Nevertheless, while low drug concentrations can be measured with LC-MS/MS, this analytical method has not reached the very low limits of detection of AMS. Hence, a larger unlabeled dose may be needed, which may increase the risk of a therapeutic or toxic effect [13] . Moreover, the use of an unlabeled microdose would also prohibit the separation of the disposition of an oral and intravenous dose given at the same time. This could be overcome by using stable isotope-labeled probe drugs, which have successfully been used to study oral bioavailability using 15 N 3 -midazolam in adults [32] . This method also has the important disadvantage that a much higher labeled drug dose is needed with similar or even higher risk of therapeutic or toxic effect.
Conclusion
We have shown proof of concept for the practical and ethical feasibility of a [
14 C]labeled microdose to study pharmacokinetics in young children. This approach offers innovative possibilities to perform phase I first-in-child studies, especially for drugs with a small therapeutic window and high toxicity. In addition, it enables studies in vulnerable populations such as critically ill neonates and studies on developmental pharmacokinetics using probe drugs for specific elimination pathways such as drugmetabolizing enzymes and renal excretion.
